Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CELG - Celgene Corporation

Previous close
108.24
108.240   100.000%

Share volume: 0
Last Updated: Wed 20 Nov 2019 10:00:00 PM CET
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
67%
Profitability 75%
Dept financing 47%
Liquidity 23%
Performance 75%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$108.24
P/E Ratio 
N/A
DAY RANGE
$108.24 - $108.24
EPS 
$0.00
52 WEEK RANGE
$58.59 - $110.70
52 WEEK CHANGE
$60.26
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$27,779,208
AVERAGE 30 VOLUME 
$11,914,744
Company detail
CEO:
Region: US
Website: http://www.celgene.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

Recent news